2022
DOI: 10.1007/s12032-022-01876-9
|View full text |Cite
|
Sign up to set email alerts
|

The clinical significance of HER2 expression in DCIS

Help me understand this report

Search citation statements

Order By: Relevance

Paper Sections

Select...
3
2

Citation Types

0
11
0

Year Published

2023
2023
2024
2024

Publication Types

Select...
9
1

Relationship

0
10

Authors

Journals

citations
Cited by 27 publications
(25 citation statements)
references
References 71 publications
0
11
0
Order By: Relevance
“…However, patients with DCIS after breast-conserving surgery had clinically significant recurrence rates, and approximately half of these cases will be life-threatening invasive recurrences. 26 Histological subtype has emerged as an important tool in predicting prognosis for breast cancer and has been shown to correlate with differences in survival with invasive micropapillary carcinoma groups having poor outcomes. 27 , 28 The bony skeleton, lung, liver, and brain are the primary targets of breast cancer metastasis.…”
Section: Discussionmentioning
confidence: 99%
“…However, patients with DCIS after breast-conserving surgery had clinically significant recurrence rates, and approximately half of these cases will be life-threatening invasive recurrences. 26 Histological subtype has emerged as an important tool in predicting prognosis for breast cancer and has been shown to correlate with differences in survival with invasive micropapillary carcinoma groups having poor outcomes. 27 , 28 The bony skeleton, lung, liver, and brain are the primary targets of breast cancer metastasis.…”
Section: Discussionmentioning
confidence: 99%
“…It is clear that women are confused by treatment options and their own personal risk 47 , which is exemplified by the poor recruitment to active monitoring trials LORIS and LORD which offered randomization to surveillance and annual mammogram for low-risk DCIS 48 and are now being re-designed. Efforts in biomarker development and testing for additional markers such as HER2 in DCIS for risk stratification, 49 50 51 combined with evidence for the use of more tolerable endocrine therapies for both invasive breast cancer and DCIS 52 , 53 should refine our treatment approaches. Patients, surgeons, and medical oncologists think that there is little evidence for supporting the use of ET at the time of a diagnosis of DCIS.…”
Section: Discussionmentioning
confidence: 99%
“…DCIS oftentimes does not progress to invasive carcinoma. However, it has high rates of life-threatening recurrences following breast-conserving surgeries [ 12 ]. Further research can investigate this technique on micropapillary carcinomas.…”
Section: Discussionmentioning
confidence: 99%